Astex Pharmaceuticals, Inc. announced that the FDA has granted orphan drug designation for the company’s novel, orally administered non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins, tolinapant, for the treatment of T-cell lymphoma.
[Astex Pharmaceuticals, Inc]